Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 1.00 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466429 | 0.81 | AR (0.92) | AR | |
| SCHEMBL6465329 | 0.80 | AR (1.00) | ARMAPTGAA | |
| SCHEMBL6465259 | 0.80 | AR (1.00) | ARMAPTPRKCZTSHRTP53 | |
| SCHEMBL6468328 | 0.79 | AR (0.76) | ARMAPTPRKCZTP53GAA | |
| SCHEMBL6466856 | 0.79 | AR (1.00) | ARMAPTPRKCZRAB9A | |
| SCHEMBL6467813 | 0.79 | AR (1.00) | ARMAPTPRKCZTSHR | |
| SCHEMBL6468262 | 0.77 | AR (0.77) | ARMAPTPRKCZGAAMAPK1 | |
| SCHEMBL6469619 | 0.76 | AR (0.75) | ARMAPTPRKCZGAARAB9A | |
| SCHEMBL6464195 | 0.76 | AR (0.74) | ARMAPTPRKCZTP53GAA | |
| SCHEMBL6469667 | 0.75 | AR (0.74) | ARMAPTPRKCZGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885ELANE 2526/4885MAPT 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.